通过在慢性乙型肝炎患者中减少核苷（t）类似物的剂量来维

StephenW

J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25443. [Epub ahead of print]
Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in chronic hepatitis B patients.
Hsu CW1,2, Yeh C3, Yeh CT1,2.
Author information

1
    Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
2
    Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan.
3
    Department of Biology, University of California, Los Angeles, USA.

Abstract

In chronic hepatitis B (CHB) patients, withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From 2008-March to 2016-September, 48 CHB patients who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for > 1 year), were placed on reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full-dose, lifelong treatment is unachievable. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

entecavir; estimated glomerular filtration rate; liver failure; tenofovir

PMID:
    30817845
DOI:
    10.1002/jmv.25443

StephenW

J Med Virol。 2019年2月28日doi：10.1002 / jmv.25443。 [印刷前的电子版]
通过在慢性乙型肝炎患者中减少核苷（t）类似物的剂量来维持完全的病毒学抑制。
Hsu CW1,2，Yeh C3，Yeh CT1,2。
作者信息

1
    台湾桃园长庚纪念医院肝脏研究中心
2
    台湾桃园长庚大学分子医学研究中心
3
    美国加利福尼亚大学洛杉矶分校生物系。

抽象

在慢性乙型肝炎（CHB）患者中，核苷（酸）类似物（NAs）的撤出可使患者处于肝炎复发的风险中。在这里，我们研究了一种剂量减少策略。从2008年至3月至2016年9月，48名接受全剂量NA（35名恩替卡韦; 13名替诺福韦）并达到完全病毒学应答（持续> 1年）的CHB患者接受减量剂量的抗病毒药物治疗（每周两次）随后。在33.2个月的中位随访期内，只有一名患者出现病毒学但未达到生化突破。未发现估计的肾小球滤过率恶化。该策略可用于无法实现全剂量终身治疗的领域。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

恩替卡韦;估计肾小球滤过率;肝功能衰竭;替诺福韦

结论：
    30817845
DOI：
    10.1002 / jmv.25443

齐欢畅